Randomised double-blind cross-over trial of proglumide in patients with chronic pain and/or fatigue

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN47564212

Enrollment

Registered

2004-09-30

Start date

2000-02-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Signs and Symptoms: Pain Respiratory 1. Pain, not elsewhere classified 2. Encephalitis, myelitis and encephalomyelitis

Interventions

Randomised double blind cross-over design. Baseline week of symptom diaries and questionnaires. Four weeks on either proglumide or inactive preparation, then mid study questionnaires. Four weeks on cr

Eligibility

Inclusion criteria

Inclusion criteria: 40

Exclusion criteria

Exclusion criteria: Does not match inclusion criteria

Design outcomes

Primary

Measure	Time frame
Primary end-point: less fearfulness (as measured by anxiety and activity avoidance) in the proglumide phase of the crossover trial.	—

Secondary

Measure	Time frame
Secondary end-points: reduced pain scores during the proglumide phase, increased fearfulness during the ascorbic acid phase in nocebo responders.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026